August 19, 2026
The Pennsylvania federal judge overseeing antitrust multidistrict litigation against generic-drug makers over alleged price-fixing has rejected a request by the pharmaceutical company defendants to set off any potential award to insurance company plaintiff Humana Inc. by $360 million given its success in separate litigation.
August 13, 2026
The U.S. arm of Glenmark Pharmaceuticals Ltd. has agreed to settle generic-drug price-fixing claims brought by Humana Inc. in three lawsuits centralized in Pennsylvania-based multidistrict litigation, according to a filing with Indian stock exchanges.
August 12, 2026
A Connecticut federal judge ruled Wednesday that G&W Laboratories Inc. must face most price-fixing claims from dozens of state attorneys general targeting generic-drug makers, teeing the shuttered company up for trial as one of four companies deemed the "core group of leaders most responsible" for the conspiracy.
August 10, 2026
A former Connecticut prosecutor and his current firm Lowey Dannenberg PC can keep representing insurers Humana Inc. and Molina Healthcare Inc. in an antitrust lawsuit against generic-drug makers, after the judge overseeing the multidistrict litigation rejected a second attempt to appeal her denial of disqualification.
August 07, 2026
A Connecticut federal court on Thursday gave a preliminary OK to a settlement between a coalition of 48 states and territories and drugmaker Glenmark Pharmaceuticals Ltd. that would pay out more than $29.6 million in restitution to eligible consumers and the coalition.
August 06, 2026
A Connecticut federal judge has set a February trial date on claims from dozens of state attorneys general that generic-drug makers conspired to artificially inflate the prices of generic topical drugs.
August 05, 2026
A Pennsylvania federal judge on Tuesday denied a bid by a number of generic drug manufacturers to dismiss two antitrust claims brought by health insurer Humana Inc. from an upcoming bellwether trial in long-running antitrust multidistrict litigation, finding they were brought within the statute of limitations.
August 03, 2026
Sandoz reached a settlement with a coalition of state enforcers on Monday, agreeing to pay $450 million to end claims against it in several cases targeting alleged price-fixing in the generic-drug industry.
July 29, 2026
The Pennsylvania federal judge overseeing the multidistrict litigation over generic-drug price-fixing claims has ruled that Humana's health economist's expert report can be admitted into evidence, rejecting several pharmaceutical companies' argument that his findings were based on a flawed methodology.
July 28, 2026
A Pennsylvania federal judge has taken Teva to task for trying to avoid being held to its admissions of price-fixing in a $225 million settlement with the U.S. Department of Justice, ruling that Humana can use those admissions in one of the first bellwether trials in sprawling multidistrict litigation.